SCHEMBL4877795

SCHEMBL4877795

Nc1cccc(S(=O)(=O)N(C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O)OC2CCCCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSD P07339 8/20 0.44
BACE1 P56817 7/20 0.44
MLNR O43193 1/20 0.43
ABCB11 O95342 1/20 0.43
LMNA P02545 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP3A5 P20815 1/20 0.43
CNR1 P21554 1/20 0.43
TBXAS1 P24557 1/20 0.43
ADRA1A P35348 1/20 0.43
BACE2 Q9Y5Z0 4/20 0.42
SPPL2A Q8TCT8 1/20 0.39
ABCB1 P08183 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
KCNH2 Q12809 1/20 0.39
SCN5A Q14524 1/20 0.39
KCND3 Q9UK17 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877803 1.00 CTSD (0.44) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4870753 0.99 CTSD (0.43) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4870747 0.99 CTSD (0.43) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4862414 0.91 CTSD (0.44) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4862405 0.91 CTSD (0.44) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4875375 0.90 CTSD (0.52) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4875377 0.90 CTSD (0.52) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4870486 0.88 KLK5 (0.46) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4870482 0.88 KLK5 (0.46) CTSDBACE1MLNRABCB11LMNA
SCHEMBL4874005 0.88 CTSD (0.42) CTSDBACE1BACE2SPPL2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US disclosed
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
EP-1086076-B1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2004-12-22 EP disclosed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 US disclosed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP CTSD 93/4885BACE1 69/4885MLNR 4045/4885
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP CTSD 93/4885BACE1 69/4885MLNR 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.